XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Receivable and Notes Receivable
 9 Months Ended
Sep. 30, 2022
Receivables [Abstract]  
Accounts Receivable and Notes Receivable Accounts Receivable and Notes Receivable
The Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable.
Accounts Receivable as of September 30, 2022 and December 31, 2021 consist of the following:
(in thousands)September 30, 2022December 31, 2021
Oral drug accounts receivable$3,212 $2,097 
Capitated accounts receivable937 665
FFS accounts receivable23,450 12,530
Clinical trials accounts receivable1,944 1,823
Other trade receivables5,277 2,892
Total$34,820 $20,007 
During the three and nine months ended September 30, 2022, the Company had net reversals of bad debt recoveries of $28 and $110, respectively and bad debt expense of $115, and $292, respectively. Bad debt write-offs were a result of accounts receivable on completed contracts that were deemed uncollectible during the period due to delayed collection efforts. During the three and nine months ended September 30, 2021, the Company had net reversals of bad debt recoveries of $38 and net bad debt recoveries of $684, respectively. There was $16 of bad debt expense recognized during the three and nine months ended September 30, 2021.